1. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses.
- Author
-
Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, and Siliciano RF
- Subjects
- CD4-Positive T-Lymphocytes cytology, Carrier State therapy, Cell Line, DNA, Viral analysis, DNA, Viral genetics, Defective Viruses genetics, Defective Viruses physiology, HIV Infections therapy, HIV-1 genetics, HIV-1 physiology, Humans, Lymphocyte Activation, Polymerase Chain Reaction, Proviruses genetics, Proviruses physiology, CD4-Positive T-Lymphocytes virology, Carrier State virology, Defective Viruses isolation & purification, HIV Infections virology, HIV-1 isolation & purification, Proviruses isolation & purification, Virus Latency
- Abstract
A stable latent reservoir for HIV-1 in resting CD4
+ T cells is the principal barrier to a cure1-3 . Curative strategies that target the reservoir are being tested4,5 and require accurate, scalable reservoir assays. The reservoir was defined with quantitative viral outgrowth assays for cells that release infectious virus after one round of T cell activation1 . However, these quantitative outgrowth assays and newer assays for cells that produce viral RNA after activation6 may underestimate the reservoir size because one round of activation does not induce all proviruses7 . Many studies rely on simple assays based on polymerase chain reaction to detect proviral DNA regardless of transcriptional status, but the clinical relevance of these assays is unclear, as the vast majority of proviruses are defective7-9 . Here we describe a more accurate method of measuring the HIV-1 reservoir that separately quantifies intact and defective proviruses. We show that the dynamics of cells that carry intact and defective proviruses are different in vitro and in vivo. These findings have implications for targeting the intact proviruses that are a barrier to curing HIV infection.- Published
- 2019
- Full Text
- View/download PDF